Physician profile
Patrick D Walker
NPI 1780768630
$9,662.98
in general payments reported to CMS, 2019-2025
45 companies · $888 in 2025
The $888 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,950 · 2020: $1,616 · 2021: $1,958 · 2022: $1,258 · 2023: $1,097 · 2024: $896 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,796 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,795.59 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,682.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sunovion Pharmaceuticals INC. | $1,426.62 | 2019-2022 | |
| Abbvie INC. | $889.38 | 2020-2025 | Vraylar |
| Lilly USA, LLC | $714.07 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $555.28 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $528.07 | 2019-2023 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $443.52 | 2019-2025 | Farxiga, Breztri |
| Allergan, INC. | $392.84 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $358.20 | 2021-2025 | Caplyta |
| Amgen INC. | $292.73 | 2019-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $229.95 | 2019-2023 | Austedo, Austedo Xr |
| Merck Sharp & Dohme LLC | $210.85 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $202.09 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $201.83 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $179.88 | 2020-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.